Introduction
Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor recently introduced into the pharmaceutical market. As with other compounds in this class, zofenopril is a prodrug that undergoes metabolic hydrolysis, releasing the corresponding active principle, zofenoprilat, whose inhibitory effect on ACE is in the nanomolar range. 1 -3 This ACE inhibitory activity was first tested in animal tissues, but has also been confirmed for human recombinant ACE (Table 1 ; unpublished data).
Zofenoprilat is characterized chemically by the presence of a sulphydryl (SH) group ( Fig. 1 ). Zofenopril and zofenoprilat are highly lipophilic, more so than other ACE inhibitors. 4, 5 The marked lipophilia of zofenopril ensures effective and long-lasting tissue penetration; 6 -8 tissue uptake and the extent and duration of the ACE inhibition at the myocardial and vascular level are better with zofenopril than with other ACE inhibitors. 1, 2, 6 Since ACE inhibitors appear to work by inhibiting ACE in critical tissues, tissue selectivity is one of the most important properties of individual drugs in this class.
Administered orally, zofenopril produces a marked, long-lasting anti-hypertensive action that is 10 times more potent than that of captopril and is effective even using only a single daily administration. 3 Zofenopril and captopril are the only ACE inhibitors with SH groups and consequent potential antioxidant activity. This activity may contribute to the notable cardio-and endothelium-protective effects of zofenopril. 9 This review highlights the available preclinical data concerning the antioxidant properties of zofenopril and its ability to protect cardiac and vascular tissue from injury and dysfunction. 
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Antioxidant activity
IN VITRO STUDIES
Studies using the photo-oxidation of riboflavin sensitized by dianisidine to generate active oxygen species have clearly defined the remarkable difference in the antioxidant action of SH-containing compared with non-SH-containing, ACE inhibitors. 10 The SH-containing, ACE inhibitors zofenopril, captopril, epicaptopril (the stereoisomer of captopril, which is devoid of ACE inhibitory properties) and fentiapril were found to be effective scavengers of non-superoxide free radicals, while four non-SH-containing ACE inhibitors were inactive. The protective effects from free radical-induced cell damage of SH-containing ACE inhibitors have also been assessed in cultured endothelial cells exposed to a superoxide anion and hydroxyl radical generating system. 11 Pre-incubation of the cells with captopril, epicaptopril or zofenopril produced a concentrationdependent (10 -200 µM) inhibition of malonyldialdehyde formation. Both loss of cell viability and membrane blebbing were reduced by SH-containing ACE inhibitors at concentrations as low as 10 µM. In contrast, lisinopril and enalaprilat were ineffective at concentrations up to 200 µM. Cominacini et al. 12 showed that zofenoprilat, but not enalaprilat, significantly (P < 0.001) and dose-dependently reduced the formation of intracellular reactive oxygen species (ROS) and superoxide induced by oxidized low density lipoprotein (ox-LDL) and tumour necrosis factor-α (TNFα) in human endothelial cells. Zofenoprilat but not enalaprilat also decreased the consumption of intracellular glutathione induced by ox-LDL and TNF-α. While zofenoprilat significantly (P < 0.01) and dose-dependently reduced the expression of vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1 and Eselectin induced by ox-LDL and TNF-α in human umbilical vein endothelial cells (HUVECs), enalaprilat did not. In addition, pre-incubation of HUVECs with zofenoprilat dose-dependently reduced the increased activation of nuclear factor-κB (NF-κB) by ox-LDL and TNF-α. 12 It is known that the migration of circulating monocytes and ox-LDL into the subendothelial space is one of the key events in atherosclerosis 13 and is mediated by the occurrence and expression of adhesion molecules on endothelial cells. NF-κB, a redox-sensitive element, is a transduction factor in the molecular gene induction of adhesion molecules. Moreover, in the study by Cominacini et al., 12 the intracellular concentrations of zofenoprilat and its penetration inside the cells was correlated with its antioxidant activity. The intracellular levels of zofenoprilat found to exert antioxidant activity (from 0.54 fmol/cell, corresponding to 250 ng/ml) were very close to the maximum concentrations found in humans (700 ng/ml). 14 Furthermore, up to 40% of the total plasma concentration of zofenoprilat is bound to lipoproteins, which may act as carriers of the drug toward the endothelium. These data confirm the lipophilic properties of zofenopril and its capability to penetrate into human endothelium, where it can exert protective antioxidant activities. Thus SH-containing ACE inhibitors, in addition to controlling blood pressure, may be useful in inhibiting atherosclerotic plaque progression, which slows the development of atherosclerosis.
The comparative effects of three ACE inhibitors on endothelial nitric oxide production and action on endothelial oxidative stress were also assessed. 15 Using bovine aortic endothelial cells (BAECs) grown to confluence, the effects of 44 S Evangelista, S Manzini Antioxidant and cardioprotective properties of zofenopril captopril, zofenoprilat and enalaprilat on nitrite/nitrate accumulation in the media, cyclic guanosine monophosphate (cGMP) accumulation in the cell lysate, and F 2isoprostanes in lipid extracts from the cells were examined. Nitrite/nitrate accumulation was used as a measure of nitric oxide production by the BAECs. Only zofenoprilat significantly (P < 0.001) enhanced nitrite/ nitrate production over the full range of concentrations used (10 -60 µM). This increase in nitrogen oxides was associated with an increase in nitric oxide bioactivity, as demonstrated by the significant (P < 0.001) increase in endothelial cell cGMP accumulation (Fig. 2 ). This effect was again notable only for zofenoprilat over the range of concentrations used; captopril also had an effect on cGMP, but only at the highest concentration tested (60 µM). F 2 -isoprostanes were reduced, with the reduction correlating with the increases in nitrite/nitrate and cGMP produced by zofenoprilat, suggesting that the benefit of zofenoprilat is, in part, a consequence of reduced oxidant stress in the 
IN VIVO STUDIES
The antioxidant properties of zofenopril demonstrated in vitro, such as the reduced oxidation of LDL and expression of adhesion molecules and improved function of endothelial cells, have been investigated using in vivo models of atherosclerosis, in which these factors play an important role in plaque formation and progression. Two classical models of experimental atherosclerosisthe Watanabe heritable hyperlipidaemic rabbit 16 and the apolipoprotein-E-deficient mouse 17 -were used. In Watanabe heritable hyperlipidaemic rabbits, zofenopril (0.5 mg/kg daily for 6 weeks) reduced plaque formation and LDL oxidation, and decreased native LDL, ox-LDL and macrophage-derived foam cells, as measured using monoclonal antibodies. 16 In addition, the zofenopriltreated group displayed reduced platelet adherence and activation at the site of the atherosclerotic lesions, shown by reduced platelet-associated radioactivity. Further investigation involved longer term administration (6 months) of zofenopril, captopril and enalapril in a genetically modified (apolipoprotein E-deficient) mouse model. 17 This study also included extensive evaluation of the histochemical parameters related to the oxidative state of the vessel wall (intimal macrophage-derived foam cells, and oxidation-specific epitopes of ox-LDL and native LDL in the aorta). The data confirmed interesting antioxidant properties for zofenopril, which were greater than those of captopril. The reduction in atherosclerotic lesions was significantly (P < 0.05) higher for zofenopril compared with captopril ( Fig. 3) . Concomitantly, the oxidation status of the aorta was reduced by zofenopril and captopril. Enalapril did not reduce the aortic lesions or influence the oxidation parameters. 17
Cardioprotective activity
IN VITRO STUDIES
Captopril (36 -1080 µM) and zofenoprilat (3.6 -36 µM) increased the coronary flow of isolated rat heart in a concentrationdependent manner; this effect was not accompanied by an increase in 6-keto prostaglandin F 1α overflow in the coronary effluent. 18 The onset of the coronary vasodilator action of ramiprilat (39 µM) was slower; the effect was significant (P < 0.05) only after 20 min of perfusion and was associated with an increase in 6-keto prostaglandin F 1α outflow, suggesting different mechanisms of action for ACE inhibitors with or without an SH group. Zofenoprilat and captopril, but not enalaprilat, potentiated the vasodilator effect of bradykinin on coronary vessels in isolated rat hearts. 18 -20 ACE inhibitors are likely to cause coronary vasodilatation via a bradykinin-mediated release of nitric oxide, which can be enhanced in the presence of free SH groups. ACE inhibitors containing free SH groups may, therefore, potentiate nitrates and reverse tolerance to their therapeutic effects, as has also been suggested by preliminary clinical evidence. 21 Several studies have investigated the cardioprotective effects of zofenopril in experimental models of global ischaemia/ reperfusion. Reperfusion releases large amounts of lactic dehydrogenase (LDH), an indicator of cell viability or membrane integrity; decreases cardiac function; and increases the end-diastolic pressure (EDP), a reflection of contracture that indicates severe damage. Zofenoprilat at 3 -10 µM and captopril at 400 µM improved contractile force and reduced EDP and LDH release during reperfusion. 22 Enalaprilat or ramiprilat (at concentrations up to 400 µM) and fosinoprilat (at concentrations up to 100 µM) had no cardioprotective effects.
In another study of cardiac ischaemia and reperfusion, 50 µM of zofenopril was compared with captopril and fosinopril at the same concentration. 20 In control-isolated rat hearts, ischaemia and reperfusion led to markedly decreased left ventricular (LV) pressure development (measured as the maximum rate of rise in LV pressure) and coronary flow, and greatly increased release of creatine kinase (CK), a sensitive indicator of membrane injury, at the end of the reperfusion period. Treatment with zofenopril or captopril improved post-ischaemic LV function, increased coronary flow and reduced CK release; fosinopril was ineffective. Ferrari et al. 23 investigated the effects of zofenopril and captopril (both at 1 µM) on the functional and metabolic damage induced by ischaemia and reperfusion in isolated rabbit hearts. Both drugs had cardioprotective effects (although zofenopril was always considerably more effective) in that they improved recovery of the developed pressure, reduced CK, noradrenaline and lactate release, but maintained Ca 2+ homeostasis and phosphorylation capacities of the mitochondria. Zofenopril, but not captopril, attenuated oxidative stress during reperfusion.
More recently, Frascarelli et al. 24 have investigated the effect of different ACE inhibitors on tissue injury in isolated rat hearts that were subjected to 30 min of ischaemia followed by 120 min of reperfusion. Zofenoprilat (10 -100 µM) significantly (P < 0.05) reduced infarct size, as estimated on the basis of triphenyltetrazolium chloride (TTC) staining; such effects were not found with enalaprilat or (Fig. 4) . Such protection was not reproduced with irbesartan, the angiotensin II receptor antagonist, and was partly abolished by the bradykinin B 2 receptor antagonist HOE 140. The cardioprotection afforded by zofenoprilat was also associated with better preservation of protein thiols at the end of ischaemia. These findings reinforce the concept that zofenopril has a specific cardioprotective effect, which might be related either to interference with bradykinin metabolism and/or to preservation of protein SH groups.
Captopril and zofenoprilat were found to enhance LV relaxation in isolated working guinea pig hearts, without significantly altering early systolic LV performance; these effects were not observed with either lisinopril or quinaprilat. 25 The effects of captopril and zofenoprilat were attenuated by haemoglobin, a nitric oxide scavenger, and HOE 140. The presence of an SH group also appears to be essential for the LV relaxant effect, which is possibly mediated by increased activity of the bradykinin-nitric oxide pathway.
IN VIVO STUDIES
The effects of zofenopril on the myocardial changes induced by sustained arterial hypertension or cardiac ischaemia have been studied in several trials. Brilla 26 showed that renovascular hypertension, induced by aortic banding and constriction of the right renal artery, was markedly reduced by oral administration of 6 mg/kg zofenopril daily for 8 weeks. In addition to the hypertension, these animals developed marked LV hypertrophy, which was inhibited by zofenopril and nifedipine but not by an equipotent dose of labetolol, irrespective of a similar reducing effect on blood pressure produced by the three different anti-hypertensives.
In another haemodynamic study in spontaneously hypertensive rats (SHRs), 27 zofenopril given daily in food for 6 months reduced the mean arterial pressure from 106 to 84 mmHg. Its effect was similar to that of hydralazine, but zofenopril also significantly (P < 0.05) reduced the LV systolic force-time integral (a measure of total ventricular load) and the LV weight to body weight ratio.
A third study compared zofenopril (10 mg/kg daily), lisinopril (10 mg/kg daily) and losartan (20 mg/kg daily) in SHRs during the development of their hypertensive status. 28 All the treatments significantly (P < 0.05) decreased blood pressure and cardiac hypertrophy, with both variables being significantly (P < 0.001) correlated. Total ventricular collagen content was similarly decreased in all treated groups. Both zofenopril and lisinopril, but not losartan, significantly (P < 0.05) increased the expression of collagen type I. Zofenopril significantly (P < 0.05) increased the expression of collagen type III and normalized the collagen type I/III ratio. Types I and III are the major types of collagen present in the myocardium in both normal and diseased tissues. Tissue with predominantly collagen type I is characterized by strength and stiffness, whereas tissues containing large amounts of collagen type III are characterized by increased elasticity. 29 The ratio of these collagen types is therefore an important predictor of the stiffness of the cardiac muscle. Similar findings obtained with captopril 30 seem to indicate that the antioxidant SH group of these ACE inhibitors may play a role in normalizing the distribution of collagen during cardiac hypertrophy. These results suggest that the effects of ACE inhibitors on different types of collagen are independent of angiotensin II formation. The ability of zofenopril to S Evangelista, S Manzini Antioxidant and cardioprotective properties of zofenopril prevent ischaemic myocardial damage has been studied in vivo in a chronic closed-chest pig model. 31 Pigs were pre-treated with zofenopril (0.5 mg/kg daily orally), 2 days prior to ischaemia induced by the inflation of a catheter balloon in the left anterior descending coronary artery over 45 min, followed by reperfusion. During reperfusion, zofenopril decreased the pressure-rate product and reduced the peak efflux of catecholamines and purine metabolites in the coronary venous effluent. After 2 weeks, electrocardiography showed the development of late potentials in all untreated animals, whereas late potentials were not observed in the zofenopril-treated animals. Moreover, zofenopril caused a significant (P < 0.05) reduction in the inducibility of sustained ventricular tachyarrhythmias.
The effects of zofenopril, epicaptopril (both at 5 mg/kg intravenously) and enalaprilat (1.5 mg/kg intravenously) given at the time of reperfusion on recovery of contractile function after 15-min occlusion of the left anterior descending coronary artery (LAD) were studied in anaesthetized openchest dogs. 32 Regional myocardial contractile function (segment shortening) was assessed by sonomicrometry. In the stunned previously ischaemic LAD bed at 3 h after reperfusion, segment shortening remained depressed, recovering to only -5% of the preocclusion baseline. All of the three drugs attenuated post-ischaemic dysfunction: segment shortening was restored to 33%, 54% and 83% of the baseline value after reperfusion in dogs treated with epicaptopril, zofenopril and enalaprilat, respectively. These improvements in segment shortening did not appear to be the result of altered oxygen supply or demand after reperfusion, since there were no differences in systemic haemodynamic parameters or myocardial blood flow between the treatment groups. The improved contractile function associated with enalaprilat treatment was largely reversed by indomethacin, which had no effect on the improved contractile function associated with zofenopril, indicating a different mechanism of action for these two drugs.
Two studies have evaluated the effects of zofenopril (12 -15 mg/kg daily in drinking water) on cardiac remodelling in rats with congestive heart failure after acute myocardial infarction (AMI) due to ligation of the left coronary artery. 19, 33 In the first study, zofenopril was administered for either 5 days (short-term treatment) or 6 weeks (long-term treatment) following AMI. 33 Both groups of animals were evaluated 6 weeks after the first treatment. Experimental AMI produced LV dilatation. Both short-and long-term treatment significantly (P < 0.05) reduced septal wall thickness, but only longterm treatment reduced the LV volume in rats with moderate size infarcts; this effect was accompanied by a decrease in the heart weight to body weight ratio. In the second study, zofenopril and spirapril (2 -2.5 mg/kg daily) were administered for 6 weeks following experimental MI. The animals were then sacrificed and the hearts removed and perfused as described by Langendorff. In control animals (not treated with ACE inhibitors) the left ventricles were enlarged and the rate of contractions was decreased in the isolated hearts. Treatment with either zofenopril or spirapril attenuated the ventricular enlargement and increased contraction rate.
The effects of zofenopril (10 mg/day for 16 weeks) on cardiac remodelling have also been evaluated in dogs with myocardial damage produced by repetitive transmyocardial direct current shock. 34, 35 In the control group, LV mass and end-diastolic S Evangelista, S Manzini Antioxidant and cardioprotective properties of zofenopril volume, evaluated by magnetic resonance imaging, were significantly (P < 0.025) increased at the end of the study. Zofenopril suppressed the increase in both LV mass and volume, whereas the α 1 -adrenoceptor antagonist terazosin or the angiotensin II receptor antagonist losartan failed to attenuate ventricular remodelling. 35 Freedman et al. 36 evaluated the cardioprotective effects of zofenopril in Golden Syrian hamsters fed a magnesium-deficient diet, which is known to produce focal myocardial necrosis and calcification. Animals were implanted subcutaneously with slowrelease pellets containing zofenoprilat, captopril, epicaptopril or enalaprilat, at the approximate dose of 1 mg/kg daily. Zofenoprilat, captopril and epicaptopril reduced both the density and the area of lesions (evaluated by morphometric analysis), while enalaprilat was virtually ineffective.
Another study 37 evaluated the effect of zofenopril in preventing cardiac injury induced by chronic doxorubicin treatment in rats. A typical sign of doxorubicin-induced cardiotoxicity is a significant (P < 0.001) lengthening of the QαT interval. This effect was completely prevented by pre-treatment with zofenopril ( Fig. 5 ). Doxorubicin treat-ment also produced impairment of the cardiac stimulatory responses induced by intravenous isoprenaline and a significant (P < 0.05) increase in relative heart weight; both of these effects were prevented by zofenopril. It is worthwhile to note that zofenopril did not interfere with the antitumour activity of doxorubicin (i.e. inhibition of tumour growth in nude mice xenografted with the A2780 human tumour cell line).
Endothelium protective activity
More than 15 years ago it was discovered that treatment of porcine aortic endothelial cells with angiotensin II produces a timedependent increase in the expression of messenger RNA for the vasoconstrictor endothelin (ET). 38 The relationships between these two important vasoconstrictor mediators have more recently been investigated in HUVECs. 39 In this study, all the ACE inhibitors tested (captopril, enalaprilat, lisinopril and zofenoprilat) reduced un-stimulated and stimulated ET-1 secretion and concomitantly increased nitric oxide prod-uction. However, zofenoprilat (-45% at 8 h) was significantly more effective (P ≤ 0.04) than enalaprilat (-30%), lisinopril (-26%) and captopril (-32%) in reducing ET-1 secretion. Similar findings were observed for nitric oxide production due to the known interference of ACE with bradykinin breakdown. These findings were probably due to the more marked antioxidant and lipophilic properties of zofenoprilat.
Zofenoprilat has also been shown to protect endothelial function, 40 abolishing the pro-apoptotic effects of doxorubicin and enhancing the survival of coronary venular endothelial cells under stress (Fig. 6 ).
Buikema et al. 41 evaluated the role of SH They compared the vasoprotective effect of chronic treatment with zofenopril versus lisinopril, or n-acetylcysteine (an SH compound) in rats with heart failure following MI. After 11 weeks of treatment, the aortas were excised and studied as ring preparations for endothelium-dependent and independent dilatation in the continuous presence of indomethacin, to avoid interference from vasoactive prostanoids. Total vasodilatation after receptordependent stimulation with acetylcholine was attenuated (-49%, P < 0.05) in untreated MI compared with control rats without MI.
This was in part due to impaired nitric oxide contribution in MI (-50%, P < 0.05 versus no MI). At the same time the capacity for generation of biologically active nitric oxide after receptor-independent stimulation with A23187 remained intact (Table 2) . Chronic treatment with n-acetylcysteine selectively restored only the nitric oxide contributions to total dilatation in response to acetylcholine. In contrast, both ACE inhibitors fully normalized total dilatation in response to acetylcholine, including the part mediated by nitric oxide; there were no significant differences between zofenopril and lisinopril ( Table 2 ). In addition, zofenopril, but not lisinopril, potentiated the effect of endogenous nitric oxide after A23187induced release from the endothelium (+100%) as well as that of exogenous nitric oxide provided by nitroglycerine (+22%) and sodium nitrite (+36%) (P < 0.05 versus no MI for all; Table 2 ).
This study showed that ACE inhibitors with an SH group have a potential advantage in the improvement of endothelial dysfunction through the increased activity of nitric oxide released from the endothelium into the vessel wall.
In a model of chronic hypertension induced by blockade of nitric oxide production by N(G)-nitro-L-arginine methyl ester, the oral administration of 15 mg/kg S Evangelista, S Manzini Antioxidant and cardioprotective properties of zofenopril daily of zofenopril for 8 weeks restored the systolic blood pressure to control values and improved the pro-inflammatory state of the vascular wall. 42 Zofenopril treatment also prevented ex vivo monocyte adhesion to the endothelium and the expression of some pro-inflammatory cytokines (interleukin-6, monocyte chemoattractant protein-1 and macrophage colony-stimulating factor). In addition, the redox state of the vascular wall, assessed by markers such as heme oxygenase-1 and tissue inhibitor of metalloproteinases-1, was restored by zofenopril.
The investigators extended this study by exploring the thrombotic risk in hypertension using the model of chronic nitric oxide synthase inhibition, by measuring the effect of chronic treatment with zofenopril on the vascular expression of factors and receptors regulating haemostasis and fibrinolysis. 43 Zofenopril restored the factors altered in hypertension (including platelet aggregation, expression of tissue factor and its inhibitor, plasma and tissue plasminogen activator inhibitor-1, and tissue plasminogen activator; Fig. 7 ), reducing the thrombotic risk associated with hypertension.
Conclusion
It has been shown that zofenopril, by virtue of its SH group, can exert antioxidant properties in cardiac and endothelial cells. These effects are achieved at a cellular (endothelium) drug concentration close to the maximum concentration detected in humans during therapy.
In various models of ischaemia/ reperfusion and post-infarction, zofenopril demonstrated a marked cardioprotective activity on both functional and biochemical parameters, which is more potent than that of other ACE inhibitors. There is also experimental evidence of strong protective effects on the endothelium (including reduction of endothelin-1 release, reduction of LDL-oxidizing capacity, and reduction of intracellular formation of ROS and superoxide anions).
In conclusion, zofenopril combines the superior features of the last-generation ACE inhibitors, in terms of potency, tissue tropism and duration of action, with a relevant antioxidant action. Zofenopril may, therefore, be considered to combine potent tissue protection activity at the cardiac and vascular levels with control of local 
